from DSSResources.com

First subjects enrolled in Docbot's pivotal study of its Ultivision(tm) AI Gastroenterology imaging platform to detect adenomas during colonoscopy

Provides real-time, expert-level analyses for endoscopic procedures; Docbot develops real-time AI-driven assistance for colonoscopy

IRVINE, Calif. and REDWOOD CITY, Calif., June 24, 2020 /PRNewswire/ -- Docbot, Inc., a privately-held company developing leading artificial intelligence (AI)-driven healthcare applications, today announced the first subjects enrolled at Gastro Health in a pivotal trial to validate Ultivision™ AI imaging platform for adenoma detection during colonoscopy screenings.

Ultivision is a software platform that enables real-time, expert-level analysis during imaging of colonoscopy and endoscopy screenings. It uses machine learning and algorithms that analyze more than 100 frames per second without lag to allow colonoscopists to consistently deliver the highest quality examination possible, aimed at potentially reducing the rate of interval colon cancers. Ultivision was developed based on over 20 million annotated images curated over seven years. Its self-annotating database allows for the algorithm to continuously learn as more exams are performed.

The AIDA (Artificial Intelligence for the Detection of Adenomas in Screening Colonoscopies) trial is a U.S. multicenter, prospective study that will enroll a total of 978 subjects across 6 sites in the U.S. The Company believes this trial could be sufficient to support the filing of a De Novo application submission for clearance of its Ultivision software for colonoscopy in the U.S.

The first subjects were enrolled at Gastro Health in Birmingham, Alabama. Gastro Health is a leading medical group of gastroenterology providers in the U.S. with more than 113 offices in Florida, Alabama, Virginia and Washington.

Robert A. Shaffer, MD, the Principal Investigator of the trial at Gastro Health, commented, "Colonoscopy has been proven to be the most effective screening modality for the prevention of colon cancer, however, the rate of new colon cancer cases in the U.S. has held steady at about 38 per 100,000 people. With my brief experience with Docbot's AI platform, I believe AI has the potential to drive these rates lower by providing an additional layer of expert imaging analysis to ensure adenomas aren't missed during exams."

"Despite the U.S. spending more than $20 billion per year on 18 million colonoscopies, colon cancer remains the second leading cause of cancer death," commented Andrew Ninh, CEO and Co-Founder of Docbot. "Many publications, including those featuring Ultivision, have shown to greatly enhance diagnostic capabilities in numerous modalities. We believe our real-time AI for colonoscopy will lead to improved detection and enhanced patient care. We look forward to having enrollment completed in the AIDA study and reporting by end of year."

James Leavitt, MD, FACG, a leading gastroenterologist and the President and Chief Clinical Officer for Gastro Health, added, "It is inevitable that artificial intelligence will be intimately integrated into health care delivery. For that reason, we at Gastro Health are excited to partner in the advancement of this technology. We feel confident that it will lead to improved patient outcomes."

About Docbot

Headquartered in California, Docbot, Inc. is a privately-held company developing leading artificial intelligence (AI)-driven healthcare applications. Its flagship product, Ultivision™, is a real-time AI image analysis platform for lesion detection during colonoscopy screenings, with a product pipeline to expand to other digestive health indications. For more information, visit https://www.docbot.co.

SOURCE Docbot, Inc.

Related Link https://www.docbot.co



DSS Home |  About Us |  Contact Us |  Site Index |  Subscribe | What's New
Please Tell 
Your Friends about DSSResources.COM Copyright © 1995-2015 by D. J. Power (see his home page). DSSResources.COMsm is maintained by Daniel J. Power. Please contact him at djpower1950 at gmail.com with questions. See disclaimer and privacy statement.